237 related articles for article (PubMed ID: 28838188)
1. Administering Multiple Injectable Vaccines During a Single Visit-Summary of Findings From the Accelerated Introduction of Inactivated Polio Vaccine Globally.
Dolan SB; Patel M; Hampton LM; Burnett E; Ehlman DC; Garon J; Cloessner E; Chmielewski E; Hyde TB; Mantel C; Wallace AS
J Infect Dis; 2017 Jul; 216(suppl_1):S152-S160. PubMed ID: 28838188
[TBL] [Abstract][Full Text] [Related]
2. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis.
Ciapponi A; Bardach A; Rey Ares L; Glujovsky D; Cafferata ML; Cesaroni S; Bhatti A
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011260. PubMed ID: 31801180
[TBL] [Abstract][Full Text] [Related]
3. Poliovirus vaccines. Progress toward global poliomyelitis eradication and changing routine immunization recommendations in the United States.
Sutter RW; Prevots DR; Cochi SL
Pediatr Clin North Am; 2000 Apr; 47(2):287-308. PubMed ID: 10761505
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age.
Arístegui J; Dal-Ré R; Díez-Delgado J; Marés J; Casanovas JM; García-Corbeira P; De Frutos E; Van Esso D; Verdaguer J; De la Flor J; Moraga F; Boceta R; García-Martínez JA
Vaccine; 2003 Sep; 21(25-26):3593-600. PubMed ID: 12922087
[TBL] [Abstract][Full Text] [Related]
5. Surveillance for poliovirus vaccine adverse events, 1991 to 1998: impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine.
Wattigney WA; Mootrey GT; Braun MM; Chen RT
Pediatrics; 2001 May; 107(5):E83. PubMed ID: 11331733
[TBL] [Abstract][Full Text] [Related]
6. Remarks on the possibility of introducing the fractionated dose of the inactivated poliomyelitis vaccine in the Latin American Child Immunization Schedule.
Arbo A; Falleiros-Arlant LH; López EL; Brea Del Castillo J; Martínez de Cuellar C; Moreno G; Rolón R; Cerda J; Eguiazú S;
Rev Chilena Infectol; 2019 Feb; 36(1):83-90. PubMed ID: 31095207
[TBL] [Abstract][Full Text] [Related]
7. Preparation for global introduction of inactivated poliovirus vaccine: safety evidence from the US Vaccine Adverse Event Reporting System, 2000-12.
Iqbal S; Shi J; Seib K; Lewis P; Moro PL; Woo EJ; Shimabukuro T; Orenstein WA
Lancet Infect Dis; 2015 Oct; 15(10):1175-1182. PubMed ID: 26289956
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: a randomized trial in the United States.
Klein NP; Abu-Elyazeed R; Cheuvart B; Janssens W; Mesaros N
Hum Vaccin Immunother; 2019; 15(4):809-821. PubMed ID: 30444673
[TBL] [Abstract][Full Text] [Related]
9. [Remarks on the possibility of the introduction of fractionated dose of the inactivated poliomyelitis vaccine in the Latin American Child Immunization Schedule].
Arbo A; Falleiros-Arlant LH; López EL; Brea Del Castillo J; Martínez de Cuellar C; Moreno G; Rolón R; Cerda J; Eguiazú S;
Rev Chilena Infectol; 2018 Aug; 35(4):395-402. PubMed ID: 30534926
[TBL] [Abstract][Full Text] [Related]
10. Experience With Inactivated Polio Vaccine Introduction and the "Switch" From Trivalent to Bivalent Oral Polio Vaccine in the World Health Organization's Western Pacific Region.
Gurung S; Harris JB; Eltayeb AO; Hampton LM; Diorditsa S; Avagyan T; Schluter WW
J Infect Dis; 2017 Jul; 216(suppl_1):S101-S108. PubMed ID: 28838170
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of a DTaP-IPV/Hib pentavalent vaccine given as primary and booster vaccinations in healthy infants and toddlers in Japan.
Nakayama T; Vidor E; Tsuzuki D; Nishina S; Sasaki T; Ishii Y; Mizukami H; Tsuge H
J Infect Chemother; 2020 Jul; 26(7):651-659. PubMed ID: 32307307
[TBL] [Abstract][Full Text] [Related]
12. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants.
Lagos R; Kotloff K; Hoffenbach A; San Martin O; Abrego P; Ureta AM; Pines E; Blondeau C; Bailleux F; Levine MM
Pediatr Infect Dis J; 1998 Apr; 17(4):294-304. PubMed ID: 9576383
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trial.
Bandyopadhyay AS; Gast C; Rivera L; Sáez-Llorens X; Oberste MS; Weldon WC; Modlin J; Clemens R; Costa Clemens SA; Jimeno J; Rüttimann R
Lancet Infect Dis; 2021 Apr; 21(4):559-568. PubMed ID: 33284114
[TBL] [Abstract][Full Text] [Related]
14. Budget impact of polio immunization strategy for India: introduction of one dose of inactivated poliomyelitis vaccine and reductions in supplemental polio immunization.
Khan MM; Sharma S; Tripathi B; Alvarez FP
Public Health; 2017 Jan; 142():31-38. PubMed ID: 28057194
[TBL] [Abstract][Full Text] [Related]
15. Acceptance of multiple injectable vaccines in a single immunization visit in The Gambia pre and post introduction of inactivated polio vaccine.
Idoko OT; Hampton LM; Mboizi RB; Agbla SC; Wallace AS; Harris JB; Sowe D; Ehlman DC; Kampmann B; Ota MO; Hyde TB
Vaccine; 2016 Sep; 34(41):5034-5039. PubMed ID: 27570237
[TBL] [Abstract][Full Text] [Related]
16. Introduction of Inactivated Poliovirus Vaccine and Impact on Vaccine-Associated Paralytic Poliomyelitis - Beijing, China, 2014-2016.
Zhao D; Ma R; Zhou T; Yang F; Wu J; Sun H; Liu F; Lu L; Li X; Zuo S; Yao W; Yin J
MMWR Morb Mortal Wkly Rep; 2017 Dec; 66(49):1357-1361. PubMed ID: 29240729
[TBL] [Abstract][Full Text] [Related]
17. Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR Recomm Rep; 1997 Jan; 46(RR-3):1-25. PubMed ID: 9026708
[TBL] [Abstract][Full Text] [Related]
18. Estimating the likely coverage of inactivated poliovirus vaccine in routine immunization: evidence from demographic and health surveys.
Anand A; Pallansch MA; Estivariz CF; Gary H; Wassilak SG
J Infect Dis; 2014 Nov; 210 Suppl 1(Suppl 1):S465-74. PubMed ID: 25316869
[TBL] [Abstract][Full Text] [Related]
19. Introduction of inactivated poliovirus vaccine in the Philippines: Effect on health care provider and infant caregiver attitudes and practices.
Lopez AL; Harris JB; Raguindin PF; Aldaba J; Morales M; Sylim P; Wannemuehler K; Wallace A; Ehlman DC; Hyde TB; Fox KK; Nyambat B; Ducusin MJ; Hampton LM
Vaccine; 2018 Nov; 36(48):7399-7407. PubMed ID: 30431003
[TBL] [Abstract][Full Text] [Related]
20. Variation in clinician recommendations for multiple injections during adoption of inactivated polio vaccine.
Lieu TA; Davis RL; Capra AM; Mell LK; Quesenberry CP; Martin KE; Zavitkovsky A; Black SB; Shinefield HR; Thompson RS; Rodewald LE
Pediatrics; 2001 Apr; 107(4):E49. PubMed ID: 11335770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]